Arcutis Biotherapeutics, Inc. Common Stock ARQT
i
Market dataready · fetched 2026-11-12T03:19:23.823Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:38:22.013620192Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T03:19:23.429456+00:00
Arcutis Biotherapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 20.60 | 372.0% | 36.0% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 27.51 | 59.2% | 5.3% | |||
| 40Δ | 29.00 | 57.1% | 5.3% | 27.94 | 63.3% | 4.9% |
| 45Δ | 28.68 | 60.0% | 4.8% | 28.37 | 67.3% | 4.5% |
| 50Δ | 28.36 | 62.8% | 4.4% | 28.79 | 71.3% | 4.0% |
| 55Δ | 28.04 | 65.7% | 3.9% | 29.22 | 75.4% | 3.6% |
| 60Δ | 27.72 | 68.5% | 3.4% | 29.65 | 79.4% | 3.2% |
| 65Δ | 27.03 | 75.0% | 2.9% | 30.14 | 83.3% | 2.8% |
| 70Δ | 25.57 | 89.3% | 2.5% | 30.90 | 86.2% | 2.3% |
| 75Δ | 24.11 | 103.6% | 2.1% | 31.66 | 89.2% | 1.9% |
| 80Δ | 22.65 | 117.9% | 1.7% | 32.43 | 92.2% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.60
- IV
- 372.0%
- B/E move
- 36.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.51
- IV
- 59.2%
- B/E move
- 5.3%
40Δ
- Pseudo strike
- 29.00
- IV
- 57.1%
- B/E move
- 5.3%
- Pseudo strike
- 27.94
- IV
- 63.3%
- B/E move
- 4.9%
45Δ
- Pseudo strike
- 28.68
- IV
- 60.0%
- B/E move
- 4.8%
- Pseudo strike
- 28.37
- IV
- 67.3%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- 28.36
- IV
- 62.8%
- B/E move
- 4.4%
- Pseudo strike
- 28.79
- IV
- 71.3%
- B/E move
- 4.0%
55Δ
- Pseudo strike
- 28.04
- IV
- 65.7%
- B/E move
- 3.9%
- Pseudo strike
- 29.22
- IV
- 75.4%
- B/E move
- 3.6%
60Δ
- Pseudo strike
- 27.72
- IV
- 68.5%
- B/E move
- 3.4%
- Pseudo strike
- 29.65
- IV
- 79.4%
- B/E move
- 3.2%
65Δ
- Pseudo strike
- 27.03
- IV
- 75.0%
- B/E move
- 2.9%
- Pseudo strike
- 30.14
- IV
- 83.3%
- B/E move
- 2.8%
70Δ
- Pseudo strike
- 25.57
- IV
- 89.3%
- B/E move
- 2.5%
- Pseudo strike
- 30.90
- IV
- 86.2%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- 24.11
- IV
- 103.6%
- B/E move
- 2.1%
- Pseudo strike
- 31.66
- IV
- 89.2%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- 22.65
- IV
- 117.9%
- B/E move
- 1.7%
- Pseudo strike
- 32.43
- IV
- 92.2%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 52.96% | |
| 58.66% | |
| 56.19% | |
| 55.13% | |
| 57.09% | |
| 57.21% | |
| 52.54% | |
| 58.67% | |
| 60.71% | |
| 59.51% |
Biotechnology
ARTV
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a…
More →ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins.…
More →ARWR
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
More →ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →ASND
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
More →ATNM
Description unavailable
More →